Drug
Poseltinib clinical trials
Also written LY3337641.
- studies test it
- 8
- open now
- 2
- in phase 3
- 0
- first study started
- 2013
Keep track of what changes. Save the poseltinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
8 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 2
Eli Lilly and Company (4) · Seoul National University Hospital (2) · Hanmi Pharmaceutical Company Limited (1) · NOBO Medicine (1)
Often tested with
Tested in the same studies.
Glofitamab (1) · Lenalidomide (1) · Golcadomide (1) · Rituximab (1)
Studies
Open first, then newest update. How each study uses poseltinib is read from its arms, and is right about nine times in ten.
Testing it · 8
- NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's LymphomaRecruitingPhase 1NOBO MedicineNCT07114367Written as NB02 (Poseltinib)
- Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell LymphomaNot yet recruitingPhase 1/2Seoul National University HospitalNCT07269639Written as Golcadomide + Poseltinib + Rituximab
- GPL in Patients with Relapsed/refractory Diffuse Large B Cell LymphomaActive, not recruitingPhase 2Seoul National University HospitalNCT05335018Written as Glofitamab, Poseltinib, Lenalidomide
- A Study of LY3337641 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT03099148Written as LY3337641 (T1)
- A Study of LY3337641 in Healthy Male ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT02914379Written as [¹⁴C]-LY3337641
- A Study of LY3337641 in Japanese and Caucasian Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT03083561Written as LY3337641
- A Study of LY3337641 in Rheumatoid ArthritisTerminatedPhase 2Eli Lilly and CompanyNCT02628028Written as LY3337641
- Safety,PK/PD, Food Effect Study of Orally Administered HM71224 in Healthy Adult Male VolunteersCompletedPhase 1Hanmi Pharmaceutical Company LimitedNCT01765478Written as HM71224 single ascending dose
Codes
What other systems call poseltinib · ClinicalTrials.gg INT001775
- MeSH (NLM) C000720850poseltinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) D01E4B1U35POSELTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27275916poseltinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C141273PoseltinibOne source FDA
- DrugBank DB16299One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000720850 | poseltinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | D01E4B1U35 | POSELTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27275916 | poseltinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C141273 | Poseltinib | One source FDA |
| DrugBank | DB16299 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.